Digital Health Global
MARCH 26, 2024
Indivi is dedicated to unlocking the immense potential of digital biomarkers in drug development and healthcare by creating a unique symbiotic intersection between expert knowledge in Data Science, Clinical Science and Advanced Analytics (including machine learning and artificial intelligence).
Society for Participatory Medicine
FEBRUARY 1, 2023
The FDA issued a series of four patient-focused drug development (PFDD) guidance documents which outline how patient co-design needs to successfully happen. After all of this time and energy expended, it’s only right that patients would be witness to accountability of pharma/biotech to incorporate our collective voice.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Healthcare IT Today
JANUARY 8, 2024
It is key for pharmaceutical companies to recognize that efficiency does not override compliance, patient safety or regulatory standards. Jane Reed, Director of Life Sciences at Linguamatics, an IQVIA company Pharmaceutical developers have always prioritized drug safety. Dave Latshaw, CEO at BioPhy 1.
Society for Participatory Medicine
JANUARY 27, 2022
Healthcare stakeholders such as health systems, pharmaceutical companies, biotech and life sciences firms, and insurance companies serve patients as end users. The same definition of patient engagement applies to industry, except that the interventions lead to more human centered design and value-based care.
Digital Health Global
JUNE 20, 2023
million from Capital Grand Est and MACSF, as well as business angels, to accelerate its development in Europe and the United States. STRASBOURG, France–(BUSINESS WIRE)– BrainTale, a French medtech deciphering white matter to enable better brain care, announces it has gathered € 4.5 Today, the company has gathered €4.5
Digital Health Global
SEPTEMBER 27, 2023
About Automera Automera is an early-stage company focused on the development of a novel therapeutic approach via autophagy-based targeted protein degradation. Since our inception in 2022, ClavystBio has committed over US$220m to biotech, diagnostics, and digital health companies, as well as early-stage VC funds.
Digital Health Global
MARCH 16, 2023
Both Wellington and Forbion are visionaries and highly experienced biotech investors, and we look forward to working closely with them in our efforts to transform the gene editing landscape.” “Our Forbion invests in life sciences companies that are active in the (bio) pharmaceutical space. Forbion manages well over EUR 2.3
Expert insights. Personalized for you.
88 
Let's personalize your content